Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Heptares Therapeutics
Biotech
AstraZeneca scraps midphase drugs from $1B buyout, Heptares pact
AstraZeneca has completed a clearout of its midphase pipeline, dumping a clutch of cancer, diabetes and cardiovascular disease drugs.
Nick Paul Taylor
Nov 12, 2021 7:30am
GSK bags rights to Sosei drugs against digestive disorder target
Dec 21, 2020 7:35am
Sosei pays £35M stake, with future buyout option, for British biotech MiNA
May 3, 2017 6:01am
EuroBiotech Report—Cell Medica, Astex, Galapagos and more
Mar 16, 2017 9:43am
Heptares adds Daiichi pain pact to string of R&D deals
Mar 13, 2017 6:46am
Heptares, Cambridge Uni team up to pursue CV target
Jan 31, 2017 5:30am
